{
    "nct_id": "NCT05534646",
    "official_title": "Phase II Study of Apalutamide with Carotuximab in Metastatic, Castration-Resistant Prostate Cancer",
    "inclusion_criteria": "* History of castration-resistant prostate cancer with rising PSA (prostate-specific antigen) on a contemporary ARSI (Androgen receptor (AR) signaling inhibitor: abiraterone, enzalutamide, darolutamide). Bicalutamide, nilutamide, and flutamide will not be considered as contemporary ARSIs\n* Patient must have had 1 and can have up to 2 prior AR targeted therapy with the exception of apalutamide.\n* Patients must decline or be ineligible for taxane therapy in the opinion of the treating physician.\n* All patients must agree to use an adequate method of contraception, in the opinion of the treating investigator, while on protocol treatment and for 3 months after the last dose of protocol treatment (apalutamide and/or carotuximab)\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Non-PSA producing prostate cancers such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise\n* Prior use of apalutamide\n* Other prior malignancy requiring active anticancer therapy\n* Prior exposure to carotuximab or any CD105 targeted antibody\n* Active bleeding or pathologic medical conditions that carries a high bleeding risk\n* A known diagnosis of Osler-Weber-Rendu syndrome",
    "miscellaneous_criteria": ""
}